Literature DB >> 26428378

Innate Immune Recognition of EBV.

Anna Lünemann1,2, Martin Rowe3, David Nadal4,5.   

Abstract

The ability of Epstein-Barr virus (EBV) to establish latency despite specific immune responses and to successfully persist lifelong in the human host shows that EBV has developed powerful strategies and mechanisms to exploit, evade, abolish, or downsize otherwise effective immune responses to ensure its own survival. This chapter focuses on current knowledge on innate immune responses against EBV and its evasion strategies for own benefit and summarizes the questions that remain to be tackled. Innate immune reactions against EBV originate both from the main target cells of EBV and from nontarget cells, which are elements of the innate immune system. Thus, we structured our review accordingly but with a particular focus on the innate recognition of EBV in its two stages in its life cycle, latent state and lytic replication. Specifically, we discuss (I) innate sensing and resulting innate immune responses against EBV by its main target cells, focusing on (i) EBV transmission between epithelial cells and B cells and their life cycle stages; and (ii) elements of innate immunity in EBV's target cells. Further, we debate (II) the innate recognition and resulting innate immune responses against EBV by cells other than the main target cells, focusing on (iii) myeloid cells: dendritic cells, monocytes, macrophages, and neutrophil granulocytes; and (iv) natural killer cells. Finally, we address (III) how EBV counteracts or exploits innate immunity in its latent and lytic life cycle stages, concentrating on (v) TLRs; (vi) EBERs; and (vii) microRNAs.

Entities:  

Keywords:  B cells; Epithelial cells; Natural killer cells; Toll-like receptors; microRNA

Mesh:

Year:  2015        PMID: 26428378     DOI: 10.1007/978-3-319-22834-1_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  7 in total

Review 1.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

2.  M1 Macrophage Polarization Prevails in Epstein-Barr Virus-Infected Children in an Immunoregulatory Environment.

Authors:  A Moyano; N M Ferressini Gerpe; E De Matteo; M V Preciado; P Chabay
Journal:  J Virol       Date:  2021-10-13       Impact factor: 6.549

3.  Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: A Case Report.

Authors:  Yue Ma; Xiaolong Sun; Wen Li; Yi Li; Tao Kang; Xiai Yang; Wen Jiang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

4.  Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.

Authors:  Antonella Farina; Giovanna Peruzzi; Valentina Lacconi; Stefania Lenna; Silvia Quarta; Edoardo Rosato; Anna Rita Vestri; Michael York; David H Dreyfus; Alberto Faggioni; Stefania Morrone; Maria Trojanowska; G Alessandra Farina
Journal:  Arthritis Res Ther       Date:  2017-02-28       Impact factor: 5.156

Review 5.  The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses.

Authors:  Jorge A Soto; Nicolas M S Gálvez; Catalina A Andrade; Gaspar A Pacheco; Karen Bohmwald; Roslye V Berrios; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

6.  HDAC6 Mediates Poly (I:C)-Induced TBK1 and Akt Phosphorylation in Macrophages.

Authors:  Yan Wang; Ke Wang; Jian Fu
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

7.  Tree Shrew Is a Suitable Animal Model for the Study of Epstein Barr Virus.

Authors:  Wei Xia; Honglin Chen; Yiwei Feng; Nan Shi; Zongjian Huang; Qingyuan Feng; Xu Jiang; Guangyao He; Mao Xie; Yongjin Lai; Zhi Wang; Xiang Yi; Anzhou Tang
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.